Skip to main content

Table 4 Treatments, sampling times, and biomarkers of tumor cells in different tissue compartments from patient 12 during disease progression

From: Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow

Date sampled Treatment Tissue compartment ER PR HER2 PIK3CA mutation in CTCs or DTCs or TCs (primary tumor or distant metastasis)
09/2002 N/A Primary Tumor 1+ rare 2+, 10% Neg (IHC 0) Wild type#
8/24/2009 Exemestane L2 vertebra bone metastasis (spine) Negative Insufficient material Insufficient material 8/8
9/23/2009 Exemestane Lung metastasis 3+, 95% Negative Neg (FISH ratio 0.56) Mutation present
9/30/2009 Tamoxifen started Blood - - - 0/3
10/8/2009 Tamoxifen Blood - - - 0/2
1/21/2010 Fulvestrant Blood - - - 0/4
2/4/2010 Fulvestrant Blood - - - 0/13
3/4/2010 Fulvestrant Bone marrow biopsy Negative Negative Negative 24/24
3/11/2010 Cyclophos-phamide started Blood - - - 10/20
4/15/2010 Cyclophos-phamide Blood - - - 2/7
7/1/2010 Cyclophos-phamide Blood - - - 0/27
8/5/2010 Capecitabine + RAD001 (everolimus) Blood - - - 0/50
10/20/2010 Capecitabine + RAD001 (everolimus) Blood - - - 0/0
11/11/2010 Capecitabine + RAD001 (everolimus) Blood - - - 0/2
  1. CTCs circulating tumor cells (from blood), DTCs disseminated tumor cells (from bone marrow), TCs tumor cells from primary tumor or metastatic site.
  2. All detected PIK3CA mutations were heterozygous on exon 9 G1633A (E545K).
  3. #Tumor cells obtained and tested from both H&E slide and formalin fixed paraffin-embedded primary tumor tissue.
  4. Tumor cells obtained and tested from H&E slide.